Previously, Wenzel served as Vice President and Head of Finance at Auregen BioTherapeutics. Before that, he was part of the European leadership team at  Roivant, where he led the European Finance organization and served as Board Member for several of the Swiss Vants. Wenzel also served as board member of Urovant Sciences GmbH, a subsidiary of Sumitomo Pharma. Earlier in his career, Wenzel held various international leadership positions of increasing responsibility at MSD (Merck). Prior to that, Wenzel held different positions at KPMG and Siemens. He holds a degree from Stralsund University of Applied Sciences and an MBA from Kristianstad University in Sweden.